Business
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical for Treatment of Non-Alcoholic Steatohepatitis (NASH)
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical for Treatment of Non-Alcoholic Steatohepatitis (NASH).
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n \n \n Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical for Treatment of Non-Alcoholic Steatohepatitis (NASH)\n \n \nEndonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical for Treatment of Non-Alcoholic Steatohepatitis (NASH)\n\nPre-Clinical Study to Determine Effectiveness of the Company's Immunotronics™ Platform in Preventing and Reversing Inflammation in Non-Alcoholic Steatohepatitis (NASH)\n\n \n LOS ANGELES, CA--(Marketwired - May 11, 2017) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions in vital organs, today announced it is commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in preventing and reversing inflammation in Non-Alcoholic Steatohepatitis (NASH). The study is the first of several currently planned studies targeting inflammatory pathologies of hepatic origin.\n \"We are delighted kick starting our liver disease pipeline targeting large and unmet clinical needs, particularly in fatty liver disease,\" commented Endonovo CEO, Alan Collier.\n The Company's Immunotronics™ platform is a non-invasive electroceutical device harnessing magnetically induced electrical field pathways in cells and organs eliciting an anti-inflammatory response in tissues and organs.\n \"NASH is an inflammatory disorder in the liver and we believe our technology represents a potentially novel and equally important, non-invasive and non-pharmaceutical treatment preventing and reversing inflammation in the liver which can cause fibrosis leading to cirrhosis and ultimately end-stage liver disease or liver cancer,\" stated Mr. Collier.\n \"In a crowded space flooded with pharmaceutical-based treatments, our platform remains highly differentiated and we believe non-invasive electroceuticals targeting inflammation in vital organs are the future of medicine,\" concluded Mr. Collier.\n About Non-Alcoholic Steatohepatitis:\n Nonalcoholic Steatohepatitis (NASH) is a condition causing inflammation and accumulation of fat and fibrous (scar) tissue in the liver. Although a similar condition can occur in people who abuse alcohol, NASH occurs in those who drink little to no...